BCG-Ulkus
Zuletzt aktualisiert: 2022-11-16
Autor(en): Anzengruber F., Navarini A.
ICD11: -
Zuletzt aktualisiert: 2022-11-16
Autor(en): Anzengruber F., Navarini A.
ICD11: -
Dieser Inhalt steht nur registrierten Nutzer:innen zur Verfügung
Therapieschema:
1. Cunha AJ, Sant'Anna CC, Mannarino R, Labanca TC, Ferreira S , March MF. Adverse effects of BCG revaccination: a report on 13 cases from Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2002;6:1110-3.
2. Kuniyuki S , Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol 1997;37:303-4.
3. Grange JM. Complications of bacille Calmette-Guerin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998;1:84-8.
4. Rees RJ. BCG vaccination in mycobacterial infections. Br Med Bull 1969;25:183-8.
5. Walsh DS, Portaels F , Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg 2008;102:969-78.
6. Thangaraj HS, Evans MR , Wansbrough-Jones MH. Mycobacterium ulcerans disease; Buruli ulcer. Trans R Soc Trop Med Hyg 1999;93:337-40.
7. Jacobsen KH , Padgett JJ. Risk factors for Mycobacterium ulcerans infection. Int J Infect Dis 2010;14:e677-81.
8. van der Werf TS, van der Graaf WT, Tappero JW , Asiedu K. Mycobacterium ulcerans infection. Lancet 1999;354:1013-8.
9. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2003;2:561-9.